Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison of Clinical Outcomes in Infantile Fibrosarcoma (IFS) Patients Treated With Larotrectinib in the Phase I/II SCOUT Study Versus (an) External Historical Cohort(s)

NCT05236257 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05236257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05236257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison of Clinical Outcomes in Infantile Fibrosarcoma (IFS) Patients Treated With Larotrectinib in the Phase I/II SCOUT Study Versus (an) External Historical Cohort(s)
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
March 10, 2022
Completion date
September 13, 2022
Enrollment
93 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infantile fibrosarcoma, locally advanced or metastatic infantile fibrosarcoma harboring an ntrk gene fusion